Liraglutide is an antidiabetic drug, a glucagon-like peptide-1 (GLP-1) analog, that blocks keratinocyte inflammatory signals by activating AMPK and inhibiting macrophage migration and is considered as a new treatment approach for psoriasis (Yang et al., 2019). This evidence concerns the gene GCG and psoriasis.